# US 12,601,741 B2 · Detection of biomarkers for non-small cell lung cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,601,741 B2 - Document ID: US12601741B2 - Status: Granted - Kind: B2 - Application number: 17/413,474 - Filed: 2019-12-12 - Published: 2022-08-18 - Granted: 2026-04-14 - Earliest claimed: 2018-12-12 - Assignees: Sengenics Sdn Bhd; National University of Singapore - Applicants: Sengenics Sdn Bhd; National University of Singapore - Inventors: Jonathan Michael Blackburn; Arif Anwar; Boon Cher Goh; Lingzhi Wang; Sok Hwee Esther Cheow; Ross Andrew Soo; Win Lwin Thuya - Web page: https://patentgrep.com/patent/US12601741B2 ## CPC - G01N 33/5752: of the lungs - G01N 33/54306: {Solid-phase reaction mechanisms} - G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9} - G01N 33/6854: {Immunoglobulins} - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract A method for diagnosing Non-Small Cell Lung Cancer (NSCLC) from a sample extracted from a subject by testing the sample for the presence of biomarkers, the biomarkers being autoantibodies against XAGE1D, LRRFIP2 and GAGE2C. Also claimed are a method of manufacturing a kit, and compositions comprising a panel of said antigens or exosomal autoantibodies. ## Claims ### Claim 1 A composition comprising a panel of antigens comprising biotinylated proteins, wherein the biotinylated proteins consist of X Antigen Family Member 1D (XAGE1D), LLR Binding FLII Interacting Protein 2 (LRRFIP2), G Antigen 2C (GAGE2C), MAGE Family Member A10 (MAGEA10), Signal Transducer and Activator of Transcription 1 (STAT 1), Zinc Ribbon Domain-Containing 1 (ZNRD1), and RAD23 Homolog B (RAD23B). ### Claim 2 (depends on 1) The composition according to claim 1 wherein each biotinylated protein is formed from a Biotin Carboxyl Carrier Protein folding marker which is fused in-frame with a protein. ### Claim 3 (depends on 1) The composition according to claim 1 wherein the biotinylated proteins are bound to a streptavidin-coated substrate. ### Claim 4 (depends on 3) The composition according to claim 3 wherein the substrate comprises a hydrogel-forming polymer base layer. ### Claim 5 (depends on 1) A composition according to claim 1 wherein the amount of one or more exosomal autoantibody biomarkers binding in vitro to the antigens in a sample from a patient can be measured to determine the presence of non-small cell lung cancer. ### Claim 6 A composition for detecting non-small cell lung cancer, which comprises a panel of antigens bound to a substrate, wherein the antigens consist of X Antigen Family Member 1D (XAGE1D), LLR Binding FLII Interacting Protein 2 (LRRFIP2), G Antigen 2C (GAGE2C), MAGE Family Member A10 (MAGEA 10), Signal Transducer and Activator of Transcription 1 (STAT 1), Zinc Ribbon Domain-Containing 1 (ZNRD 1), and RAD23 Homolog B (RAD23B). ### Claim 7 (depends on 6) The composition according to claim 6, wherein the substrate comprises a glass slide, biochip, strip, slide, bead, microtitre plate well, surface plasmon resonance support, microfluidic device, thin film polymer base layer, hydrogel-forming polymer base layer, or any other device or technology suitable for detection of antibody-antigen binding. ### Claim 8 (depends on 6) The composition according to claim 6, wherein the antigens are biotinylated proteins. ### Claim 9 (depends on 8) The composition according to claim 8, wherein each biotinylated protein is formed from a Biotin Carboxyl Carrier Protein folding marker which is fused in-frame with a protein. ### Claim 10 (depends on 6) The composition according to claim 6, wherein the substrate is streptavidin-coated. ### Claim 11 (depends on 6) The composition according to claim 6, wherein the substrate comprises a hydrogel-forming polymer base layer. ### Claim 12 (depends on 6) The composition according to claim 6 wherein the amount of one or more exosomal autoantibody biomarkers binding in vitro to the antigens in a sample from a patient can be measured to determine the presence of non-small cell lung cancer. ### Claim 13 A composition for detecting non-small cell lung cancer, which comprises a panel of antigens comprising biotinylated proteins, wherein the biotinylated proteins consist of X Antigen Family Member 1D (XAGE1D), LLR Binding FLII Interacting Protein 2 (LRRFIP2), G Antigen 2C (GAGE2C), MAGE Family Member A10 (MAGEA 10), Signal Transducer and Activator of Transcription 1 (STAT 1), Zinc Ribbon Domain-Containing 1 (ZNRD 1), and RAD23 Homolog B (RAD23B). ### Claim 14 (depends on 13) The composition according to claim 13, wherein each biotinylated protein is formed from a Biotin Carboxyl Carrier Protein folding marker which is fused in-frame with a protein. ### Claim 15 (depends on 13) The composition according to claim 13, wherein the antigens are bound to a substrate. ### Claim 16 (depends on 15) The composition according to claim 15, wherein the substrate is streptavidin-coated. ### Claim 17 (depends on 15) The composition according to claim 15, wherein the substrate comprises a hydrogel-forming polymer base layer. ### Claim 18 (depends on 15) The composition according to claim 15, wherein the substrate comprises a glass slide, biochip, strip, slide, bead, microtitre plate well, surface plasmon resonance support, microfluidic device, thin film polymer base layer, hydrogel-forming polymer base layer, or any other device or technology suitable for detection of antibody-antigen binding. ### Claim 19 (depends on 13) The composition according to claim 13 wherein the amount of one or more exosomal autoantibody biomarkers binding in vitro to the antigens in a sample from a patient can be measured to determine the presence of non-small cell lung cancer.